<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The purpose of this study was to assess the effect of <z:chebi fb="0" ids="5383">glimepiride</z:chebi> on insulin sensitivity and secretion in subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: After a 2-week washout from prior <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> therapy, 11 <z:mp ids='MP_0001261'>obese</z:mp> subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> underwent euglycemic and hyperglycemic clamp studies before and during <z:chebi fb="0" ids="5383">glimepiride</z:chebi> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: <z:chebi fb="0" ids="5383">Glimepiride</z:chebi> resulted in a 2.4-mmol/l decrease in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (P = 0.04) that was correlated with reductions in postabsorptive endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (EGP) (16.4 +/- 0.6 vs. 13.5 +/- 0.5 micro mol </plain></SENT>
<SENT sid="3" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="4" pm="."><plain>min(-1), P = 0.01) (r = 0.21, P = 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>Postabsorptive EGP on <z:chebi fb="0" ids="5383">glimepiride</z:chebi> was similar to that of control subjects (12.8 +/- 0.9 micro mol </plain></SENT>
<SENT sid="6" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="7" pm="."><plain>min(-1), NS) </plain></SENT>
<SENT sid="8" pm="."><plain>Fasting plasma insulin (66 +/- 18 vs. 84 +/- 48 pmol/l, P = 0.05), and first-phase (19 +/- 8 vs. 32 +/- 11 pmol/l, P = 0.04) and second-phase incremental insulin responses to <z:chebi fb="105" ids="17234">glucose</z:chebi> (48 +/- 23 vs. 72 +/- 32 pmol/l, P = 0.02) improved with <z:chebi fb="0" ids="5383">glimepiride</z:chebi> therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Insulin sensitivity did not change with treatment (4.6 +/- 0.7 vs. 4.3 +/- 0.7 micro mol </plain></SENT>
<SENT sid="10" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="11" pm="."><plain>min(-1) </plain></SENT>
<SENT sid="12" pm="."><plain>pmol(-1)) and remained below that of control subjects (8.1 +/- 1.8 micro mol </plain></SENT>
<SENT sid="13" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="14" pm="."><plain>min(-1) </plain></SENT>
<SENT sid="15" pm="."><plain>pmol(-1), P = 0.04) </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSIONS: The current study demonstrates that <z:chebi fb="0" ids="5383">glimepiride</z:chebi> improves both first and second phases of insulin secretion, but not insulin sensitivity, in individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>